Yongtai Technology announced that its wholly-owned subsidiary Binhai Meikang Pharmaceutical Co., Ltd. recently received the “Drug Registration Certificate” for riproduocaine cream approved and issued by the State Drug Administration. This drug is mainly used for topical skin anesthesia, such as acupuncture and superficial surgery. According to statistics, in 2024, the sales volume of riprocaine cream in public medical institutions in China was approximately RMB 615 million. The approval of this product will enrich the company's product line, enhance market competitiveness, and have a positive impact on business performance.

Yongtai Technology announced that its wholly-owned subsidiary Binhai Meikang Pharmaceutical Co., Ltd. recently received the “Drug Registration Certificate” for riproduocaine cream approved and issued by the State Drug Administration. This drug is mainly used for topical skin anesthesia, such as acupuncture and superficial surgery. According to statistics, in 2024, the sales volume of riprocaine cream in public medical institutions in China was approximately RMB 615 million. The approval of this product will enrich the company's product line, enhance market competitiveness, and have a positive impact on business performance.